These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 21712496)

  • 21. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.
    Recsky MA; Brumme ZL; Chan KJ; Wynhoven B; Yip B; Dong WW; Heath KV; Montaner JS; Levy AR; Hogg RS; Harrigan PR
    J Infect Dis; 2004 Jul; 190(2):285-92. PubMed ID: 15216463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological exposure and the development of drug resistance in HIV.
    Hoetelmans R
    Antivir Ther; 2001; 6 Suppl 2():37-47. PubMed ID: 11678477
    [No Abstract]   [Full Text] [Related]  

  • 23. A multicentre cohort experience with double-boosted protease inhibitors.
    Stebbing J; Scourfield A; Koh G; Taylor C; Taylor S; Wilkins E; Gazzard B; Nelson M; Jones R
    J Antimicrob Chemother; 2009 Aug; 64(2):434-5. PubMed ID: 19474068
    [No Abstract]   [Full Text] [Related]  

  • 24. Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy.
    Jlizi A; Ben Ammar El Gaaied A; Slim A; Tebourski F; Ben Mamou M; Ben Chaabane T; Letaief-Omezzine A; Chakroun M; Garbouj M; Ben Rejeb S
    Arch Virol; 2008; 153(6):1103-8. PubMed ID: 18483694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human immunodeficiency virus protease inhibitors.
    Kline MW
    Pediatr Infect Dis J; 2003 Dec; 22(12):1085-7. PubMed ID: 14688570
    [No Abstract]   [Full Text] [Related]  

  • 26. Antiapoptotic activity by HIV protease inhibitors either alone or boostered.
    Matarrese P; Giammarioli AM; Cauda R; Malorni W
    J Acquir Immune Defic Syndr; 2002 Dec; 31(5):545-6. PubMed ID: 12473846
    [No Abstract]   [Full Text] [Related]  

  • 27. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.
    Pozniak A; Gazzard B; Anderson J; Babiker A; Churchill D; Collins S; Fisher M; Johnson M; Khoo S; Leen C; Loveday C; Moyle G; Nelson M; Peter B; Phillips A; Pillay D; Wilkins E; Williams I; Youle M;
    HIV Med; 2003 Oct; 4 Suppl 1():1-41. PubMed ID: 14511246
    [No Abstract]   [Full Text] [Related]  

  • 28. Toxicity of antiretroviral therapy and implications for drug development.
    Carr A
    Nat Rev Drug Discov; 2003 Aug; 2(8):624-34. PubMed ID: 12904812
    [No Abstract]   [Full Text] [Related]  

  • 29. Use of HIV protease inhibitors as pharmacoenhancers.
    Moyle G
    AIDS Read; 2001 Feb; 11(2):87-98; quiz 107-8. PubMed ID: 11279888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update of the drug resistance mutations in HIV-1: 2004.
    Johnson VA; Brun-Vézinet F; Clotet B; Conway B; D'Aquila RT; Demeter LM; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD
    Top HIV Med; 2004; 12(4):119-24. PubMed ID: 15516709
    [No Abstract]   [Full Text] [Related]  

  • 31. Saquinavir, the pioneer antiretroviral protease inhibitor.
    la Porte CJ
    Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1313-22. PubMed ID: 19737048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response of severe HIV-associated thrombocytopenia to highly active antiretroviral therapy including protease inhibitors.
    Carbonara S; Fiorentino G; Serio G; Maggi P; Ingravallo G; Monno L; Bruno F; Coppola S; Pastore G; Angarano G
    J Infect; 2001 May; 42(4):251-6. PubMed ID: 11545567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [HIV-1 protease inhibitors: cell metabolism and drug resistance (review)].
    Bobkova MR
    Ter Arkh; 2008; 80(10):77-80. PubMed ID: 19105421
    [No Abstract]   [Full Text] [Related]  

  • 34. [HIV viral dynamic after antiretroviral treatment initiation: is a rapid decay a good pronostic?].
    Delaugerre C
    Pathol Biol (Paris); 2010 Dec; 58(6):403-5. PubMed ID: 19481371
    [No Abstract]   [Full Text] [Related]  

  • 35. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors.
    Introcaso CE; Hines JM; Kovarik CL
    J Am Acad Dermatol; 2010 Oct; 63(4):549-61; quiz 561-2. PubMed ID: 20846563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New trends in HIV].
    Volkert R
    Dtsch Med Wochenschr; 1998 Sep; 123(38):A7. PubMed ID: 9787287
    [No Abstract]   [Full Text] [Related]  

  • 37. Genotype and antiretroviral drug resistance of human immunodeficiency virus-1 in Saudi Arabia.
    Jamjoom GA; Azhar EI; Madani TA; Hindawi SI; Bakhsh HA; Damanhouri GA
    Saudi Med J; 2010 Sep; 31(9):987-92. PubMed ID: 20844809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [HIV protease inhibitors. A new drug class in antiretroviral therapy].
    Mauss S; Seidlitz B; Jablonowski H; Häussinger D
    Dtsch Med Wochenschr; 1996 Nov; 121(44):1369-74. PubMed ID: 8964223
    [No Abstract]   [Full Text] [Related]  

  • 39. Tribulations and trials in HIV disease, Part 2.
    Boyle BA
    AIDS Read; 2006 Jun; 16(6):291-4. PubMed ID: 16795918
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment strategies for highly treatment-experienced HIV-infected patients.
    Luber AD
    Expert Rev Anti Infect Ther; 2005 Oct; 3(5):815-23. PubMed ID: 16207173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.